Becton Dickinson's board of directors boosted its quarterly dividend to 54.5 cents per common share, up 10% from the previous quarter.
Johnson & Johnson's $2.5 billion-plus agreement to settle as many as 8,000 lawsuits over faulty metal hip implants made by its subsidiary, DePuy, is already getting pushback. Patients complain their attorneys and the company itself gain more than they do from the deal, and if discontent rises, it could place the overall agreement at risk.
U.K. orthopedics giant Smith & Nephew has been riding its checkbook into emerging markets all year, and now the company has signed a deal to pick up a share of its Brazilian wound care partner with an eye on vertical integration.
Gilde Healthcare is ramping up a new $200 million fund with plans to invest, in part, in promising early and mid-stage medical device, diagnostic and drug companies focused on developing lower-cost products.
Hospira's long-troubled infusion pump business is dealing with another recall, earning the FDA's most severe warning over a device malfunction the agency said can lead to serious injury and death.
Now that activist investor Carl Icahn has shown his hand of Hologic shares, the sluggish diagnostic giant is likely to attract some buyout attention, and analysts are split on whether the company should sell itself outright or flip its individual units.
Boston Scientific won FDA approval for yet another next-generation drug-eluting coronary stent system and has immediately ramped up its marketing machine to pursue new sales.
Direct-to-consumer DNA testing outfit 23andMe has run afoul of the FDA, and the agency served up a warning letter demanding that the company take its genetic screens off the market until it gets the proper clearance.
Novo Nordisk won the endorsement of a key European regulatory committee for a device designed to work in tandem with a Roche insulin pump to help simplify treatment for diabetics. A CE marking is likely and could open lucrative doors for both companies.
Sorin nailed down a CE mark for an XL version of the company's Perceval sutureless aortic valve.
France's Pixium Vision reeled in $20.3 million in new financing to help further development of the company's retinal implant system designed to help people with certain degenerative eye conditions see better.
Sorin gained a crucial CE mark for a new biological aortic valve replacement that doesn't leave a stent behind.
Oxford Immunotec Global's Nasdaq debut is relatively modest, though initial trading appeared to boost the price. The developer of a tuberculosis blood test priced its initial shares below range, a sign that the fall surge of diagnostics and medical device IPOs may have peaked.
Unscrupulous attorneys may exploit Johnson & Johnson's ($JNJ) offer to pay $2.5 billion-plus to settle thousands of lawsuits alleging it sold faulty metal hip implants, a New Jersey judge warned.
Johnson & Johnson's bid to unload its Ortho Clinical Diagnostics arm has moved to the next phase, with executives whittling its list of potential buyers down to three interested parties. Expect the winning bidder to emerge before the end of 2013.
Cyberonics' stock soared nearly 7% Nov. 21 in the wake of record fiscal 2014 second-quarter sales reported by the neurostimulation device company. That good news has also led to revised, higher earnings guidance for the rest of the fiscal year.
Covidien is expanding in Florida, even as the devicemaker plans to slash jobs, closes facilities and pursues outsourcing in a global money-saving move.
Cardiac device maker Abiomed surged on The Street over the last month, with eager investors pushing the company's stock price up more than 34% since October. The Massachusetts outfit's continued success growing its heart pump revenue is helping to drive the trend, ripening its desirability as a takeover target.
Oft-downgraded diagnostics giant Hologic is looking to fend off an unwanted takeover, adopting a poison pill plan after famed corporate raider Carl Icahn revealed a 12.6% stake in the company.
OraSure Technologies is ending a deal with Roche Diagnostics to develop tests that can screen for substance abuse. But the Pennsylvania company has quickly cozied up to a new collaborator: Thermo Fisher Scientific.